Bioprocessing solutions for monoclonal antibodies (mAbs)
Monoclonal antibodies (mAbs) are the largest sector in the biologics market based on revenues and drug pipelines. The clinical benefit of mAbs has been demonstrated in the treatment of autoimmune diseases and oncology.
The industry is evolving, with major investments focusing on the development of mAbs for the growing field of immuno-oncology or immunotherapy. New efforts include process optimization to increase mAb titers, mAb fragments that can be manufactured in other expression systems, multiple target specificity for mAbs, and the development of Antibody-Drug Conjugates (ADCs) that deliver highly toxic drugs to targeted cancer cells.
Products for upstream, downstream, and drug product processing offered by VWR, part of Avantor address the need to maintain mAbs quality, activity, and stability throughout the entire process. We match our supply chain of products for mammalian expression systems to meet the complexity of mAbs manufacturing — from process development and scale-up, through commercial manufacturing to final fill.